AHSA1

Summary

AHSA1 (activator of HSP90 ATPase activity 1, HGNC:1189) is a protein-coding gene on chromosome 14q24.3, encoding Activator of 90 kDa heat shock protein ATPase homolog 1 (O95433). Acts as a co-chaperone of HSP90AA1.

Enables several functions, including ATPase activator activity; Hsp90 protein binding activity; and unfolded protein binding activity. Involved in maintenance of unfolded protein and positive regulation of ATP-dependent activity. Located in cytosol.

Source: NCBI Gene 10598 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 55 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_012111

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1189
Approved symbol	AHSA1
Name	activator of HSP90 ATPase activity 1
Location	14q24.3
Locus type	gene with protein product
Status	Approved
Aliases	p38, Aha1, hAha1
Ensembl gene	ENSG00000100591
Ensembl biotype	protein_coding
OMIM	608466
Entrez	10598

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 14 protein_coding, 4 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000216479, ENST00000535854, ENST00000553374, ENST00000554156, ENST00000555133, ENST00000555457, ENST00000555473, ENST00000555517, ENST00000555729, ENST00000556369, ENST00000556866, ENST00000556963, ENST00000557476, ENST00000855620, ENST00000855621, ENST00000855622, ENST00000855623, ENST00000855624, ENST00000855625, ENST00000920448, ENST00000962103

RefSeq mRNA: 2 — MANE Select: NM_012111 NM_001321441, NM_012111

CCDS: CCDS9863

Canonical transcript exons

ENST00000216479 — 9 exons

Exon	Start	End
ENSE00000659332	77464598	77464686
ENSE00002231515	77458093	77458269
ENSE00002518265	77469077	77469472
ENSE00003459165	77462160	77462242
ENSE00003494699	77465539	77465667
ENSE00003502147	77468457	77468508
ENSE00003557959	77468083	77468184
ENSE00003603642	77462642	77462759
ENSE00003606379	77459616	77459806

Expression profiles

Bgee: expression breadth ubiquitous, 302 present calls, max score 99.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 107.8111 / max 1359.0198, expressed in 1827 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
140781	98.9067	1827
140782	7.9085	1595
140780	0.9959	603

Top tissues by expression

303 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	99.12	gold quality
right testis	UBERON:0004534	98.98	gold quality
secondary oocyte	CL:0000655	98.97	gold quality
left testis	UBERON:0004533	98.94	gold quality
right uterine tube	UBERON:0001302	98.92	gold quality
cortical plate	UBERON:0005343	98.73	gold quality
ventricular zone	UBERON:0003053	98.63	gold quality
ganglionic eminence	UBERON:0004023	98.62	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.39	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.37	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.33	gold quality
adrenal tissue	UBERON:0018303	98.32	gold quality
prefrontal cortex	UBERON:0000451	98.31	gold quality
right frontal lobe	UBERON:0002810	98.30	gold quality
body of uterus	UBERON:0009853	98.26	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.25	gold quality
lower esophagus	UBERON:0013473	98.24	gold quality
mucosa of transverse colon	UBERON:0004991	98.23	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.17	gold quality
right adrenal gland	UBERON:0001233	98.15	gold quality
left adrenal gland	UBERON:0001234	98.15	gold quality
rectum	UBERON:0001052	98.13	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.12	gold quality
left adrenal gland cortex	UBERON:0035825	98.11	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.06	gold quality
cerebellar hemisphere	UBERON:0002245	98.01	gold quality
adenohypophysis	UBERON:0002196	97.99	gold quality
cerebellar cortex	UBERON:0002129	97.98	gold quality
islet of Langerhans	UBERON:0000006	97.96	gold quality
testis	UBERON:0000473	97.96	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting AHSA1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-4524A-5P	99.57	71.73	1193
HSA-MIR-4524B-5P	99.57	71.68	1195
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-374B-3P	98.63	68.24	1360
HSA-MIR-378H	98.43	66.16	545
HSA-MIR-3190-3P	97.61	66.95	1406
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-4491	96.53	66.20	935
HSA-MIR-4657	96.53	66.57	895
HSA-MIR-4740-5P	96.25	67.96	726
HSA-MIR-4323	93.93	63.89	656

Literature-anchored findings (GeneRIF, showing 17)

• stimulates the inherent ATPase activity of Hsp90 (PMID:12504007)
• Hsp90 cochaperones modulate Hsp90-dependent stability of CFTR protein folding in the endoplasmic reticulum (PMID:17110338)
• Data propose a model for Aha1 in the Hsp90 ATPase cycle where Aha1 regulates dwell time of Hsp90, and suggest Aha1 activity integrates chaperone function with client folding energetics by modulating ATPase sensitive dimer structural transitions. (PMID:20089831)
• The interaction of Aha1 with Hsp90 and its co-chaperones in rabbit reticulocyte lysate (RRL) and in HeLa cell extracts, was characterized. (PMID:22504172)
• Hsp90 phosphorylation on tyrosine313 promotes recruitment of AHA1, which stimulates Hsp90 ATPase activity, furthering the chaperoning process. (PMID:22727666)
• Modulation of Hsp90 activity by AHA1 regulates VEGF signaling to eNOS and angiogenesis. (PMID:22859491)
• Aha1 may promote disposal of folding defective proteins by the cellular protein quality control. (PMID:25378400)
• These results suggest that differences in the middle domain of Hsp90alpha and Hsp90beta may be responsible for the isoform-specific interactions with selected proteins. (PMID:25486457)
• Aha1 colocalized with tau pathology in brain tissue, and this association positively correlated with Alzheimer disease progression. (PMID:28827321)
• Data support the multi-step nature of the Hsp90/Aha1-interaction, where the N-terminal domain of Aha1 interacts with both Hsp90 M domains upon induction of a partially closed conformation of the Hsp90 dimer. In addition, the data indicate that the C-terminal domain of Aha1 can adopt several conformations leading to a dynamic, polymorphic complex. (PMID:31299134)
• Aha-type co-chaperones: the alpha or the omega of the Hsp90 ATPase cycle? (PMID:31782942)
• AHA1 upregulates IDH1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma. (PMID:33468990)
• Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and in vitro Studies. (PMID:35034596)
• The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma. (PMID:35757728)
• p23 and Aha1: Distinct Functions Promote Client Maturation. (PMID:36520307)
• Human Aha1’s N-terminal extension confers it holdase activity in vitro. (PMID:37486705)
• Recruitment of Ahsa1 to Hsp90 is regulated by a conserved peptide that inhibits ATPase stimulation. (PMID:38937628)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ahsa1a	ENSDARG00000028664
danio_rerio	ahsa1b	ENSDARG00000100317
mus_musculus	Ahsa1	ENSMUSG00000021037
rattus_norvegicus	Ahsa1	ENSRNOG00000048981
drosophila_melanogaster	CG1416	FBGN0032961
caenorhabditis_elegans		WBGENE00007235

Protein

Protein identifiers

Activator of 90 kDa heat shock protein ATPase homolog 1 — O95433 (reviewed: O95433)

Alternative names: p38

All UniProt accessions (6): O95433, G3V3W9, G3V438, H0YJ63, H0YJG7, H0YJU2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a co-chaperone of HSP90AA1. Activates the ATPase activity of HSP90AA1 leading to increase in its chaperone activity. Competes with the inhibitory co-chaperone FNIP1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins. Competes with the inhibitory co-chaperone TSC1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins.

Subunit / interactions. Interacts with HSPCA/HSP90. Interacts (phosphorylated on Tyr-223) with HSP90AA1; the interaction activates HSP90AA1 ATPase activity. Interacts with HSP90AB1. Interacts with GCH1. Interacts with SRPK1. Interacts with FLCN. (Microbial infection) Interacts with vesicular stomatitis virus glycoprotein (VSV G) (via cytoplasmic tail).

Subcellular location. Cytoplasm. Cytosol. Endoplasmic reticulum.

Tissue specificity. Expressed in numerous tissues, including brain, heart, skeletal muscle and kidney and, at lower levels, liver and placenta.

Post-translational modifications. Phosphorylation at Tyr-223 enhances binding to chaperone HSP90AA1.

Induction. By heat shock and treatment with the HSP90 inhibitor 17-demethoxygeldanamycin (17AAG).

Similarity. Belongs to the AHA1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O95433-1	1	yes
O95433-2	2

RefSeq proteins (2): NP_001308370, NP_036243* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013538	ASHA1/2-like_C	Domain
IPR015310	AHSA1-like_N	Domain
IPR023393	START-like_dom_sf	Homologous_superfamily
IPR036338	Aha1	Homologous_superfamily

Pfam: PF08327, PF09229

UniProt features (37 total): strand 14, helix 7, modified residue 5, turn 5, cross-link 2, chain 1, sequence conflict 1, splice variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
8Z3H	X-RAY DIFFRACTION	1.5
8Z3J	X-RAY DIFFRACTION	1.52
1X53	SOLUTION NMR
7DMD	SOLUTION NMR
7DME	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95433-F1	81.10	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 3, 193, 212, 223, 258, 182, 203

Mutagenesis-validated functional residues (1):

Position	Phenotype
223	phosphomimetic mutant. increases the binding to hsp90aa1 resulting in tsc1 dissociation from hsp90aa1.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 182 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, BASSO_B_LYMPHOCYTE_NETWORK, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MORF_HDAC2, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, PUJANA_CHEK2_PCC_NETWORK, YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_PROTEIN_MATURATION, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, chr14q24, MORF_BUB3, GOBP_PROTEIN_FOLDING, GOBP_REGULATION_OF_PROTEIN_STABILITY, TIEN_INTESTINE_PROBIOTICS_24HR_UP

GO Biological Process (3): protein folding (GO:0006457), positive regulation of ATP-dependent activity (GO:0032781), obsolete maintenance of unfolded protein (GO:0036506)

GO Molecular Function (7): ATPase activator activity (GO:0001671), protein folding chaperone (GO:0044183), cadherin binding (GO:0045296), obsolete unfolded protein binding (GO:0051082), protein-folding chaperone binding (GO:0051087), Hsp90 protein binding (GO:0051879), protein binding (GO:0005515)

GO Cellular Component (4): endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ATP-dependent activity	2
cytoplasm	2
cellular anatomical structure	2
cellular process	1
protein maturation	1
regulation of ATP-dependent activity	1
positive regulation of molecular function	1
molecular function activator activity	1
molecular_function	1
protein folding	1
cell adhesion molecule binding	1
protein binding	1
heat shock protein binding	1
binding	1
endomembrane system	1
intracellular membrane-bounded organelle	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1975 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AHSA1	HSP90AA1	P07900	998
AHSA1	HSP90AB1	P08238	995
AHSA1	PTGES3	Q15185	974
AHSA1	STIP1	P31948	968
AHSA1	HSPA4	P34932	953
AHSA1	CDC37	Q16543	935
AHSA1	FKBP4	Q02790	895
AHSA1	UNC45A	Q9H3U1	827
AHSA1	CFTR	P13569	808
AHSA1	DNAJB1	P25685	795
AHSA1	DNAJA1	P31689	722
AHSA1	HSPA8	P11142	717
AHSA1	SRPK1	Q96SB4	717
AHSA1	STUB1	Q9UNE7	710
AHSA1	UNC45B	Q8IWX7	703

IntAct

112 interactions, top by confidence:

A	B	Type	Score
AHSA1	HSP90AB1	psi-mi:“MI:0882”(atpase reaction)	0.770
HSP90AB1	AHSA1	psi-mi:“MI:0915”(physical association)	0.770
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
HSP90AA1	CHUK	psi-mi:“MI:0914”(association)	0.670
AHSA1	HSP90AA1	psi-mi:“MI:0915”(physical association)	0.660
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
AICDA	DNAJA2	psi-mi:“MI:0914”(association)	0.570
AHSA1	EGFR	psi-mi:“MI:0915”(physical association)	0.550
EGFR	AHSA1	psi-mi:“MI:0915”(physical association)	0.550
HSP90AA1	USP19	psi-mi:“MI:0914”(association)	0.530
GCH1	AHSA1	psi-mi:“MI:0915”(physical association)	0.510
AHSA1	GCH1	psi-mi:“MI:0915”(physical association)	0.510
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
AHSA1	H2BC21	psi-mi:“MI:0915”(physical association)	0.400
IRF3	AHSA1	psi-mi:“MI:0915”(physical association)	0.400
rep	AHSA1	psi-mi:“MI:0915”(physical association)	0.370
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
NFKB1	NFKB1	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350

BioGRID (394): AHSA1 (Affinity Capture-MS), AHSA1 (Affinity Capture-Western), ACADM (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), AHSA1 (Co-fractionation), ASNS (Co-fractionation), ATP5C1 (Co-fractionation), C12orf10 (Co-fractionation), CCT6A (Co-fractionation)

ESM2 similar proteins: A6QQC0, A8MVJ9, B8ARK7, B9RBT0, G5ECQ8, G5EES6, I1R9A6, O82631, O94436, O95433, P06625, P08240, P13021, P32192, P34685, P40123, P40124, P52481, P53834, Q01518, Q03606, Q08163, Q11208, Q12449, Q16KN5, Q3MHE8, Q3SYV4, Q55DB6, Q5NBJ3, Q5R5X8, Q5YLB4, Q719I0, Q7EYV7, Q7KRR5, Q7PWB1, Q7XVN7, Q7XWV4, Q8BK64, Q8N9S3, Q9CYT6

Diamond homologs: A6QQC0, O95433, Q55DB6, Q719I0, Q8BK64, Q8N9S3, P53834

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
AHSA1	“up-regulates activity”	HSP90AA1	binding
AHSA1	“up-regulates activity”	HSP90AB1	binding
AHSA1	“up-regulates activity”	GCH1	binding
ABL1	“up-regulates activity”	AHSA1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 128 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ERBB2 ECD mutants	5	35.7×	1e-04
Apoptotic execution phase	5	25.3×	1e-04
Signaling by ERBB2 TMD/JMD mutants	5	25.3×	1e-04
Signaling by ERBB2 KD Mutants	5	22.5×	1e-04
Downregulation of ERBB2 signaling	5	20.2×	2e-04
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	6	12.3×	3e-04
ESR-mediated signaling	8	10.9×	1e-04
Infectious disease	12	3.2×	1e-02

GO biological processes:

GO term	Partners	Fold	FDR
intrinsic apoptotic signaling pathway	5	15.6×	6e-03
JNK cascade	5	11.8×	9e-03
protein folding	11	9.9×	2e-05
positive regulation of ERK1 and ERK2 cascade	8	5.9×	9e-03
protein phosphorylation	9	5.3×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	32
Likely benign	3
Benign	7

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2426709	NC_000014.8:g.(?77893959)(78082922_?)del	Pathogenic

SpliceAI

675 predictions. Top by Δscore:

Variant	Effect	Δscore
14:77458266:ACTGG:A	donor_loss	1.0000
14:77458267:CTGGT:C	donor_loss	1.0000
14:77458268:TGGTG:T	donor_loss	1.0000
14:77458269:GGTGA:G	donor_loss	1.0000
14:77458270:G:GG	donor_gain	1.0000
14:77458270:G:T	donor_loss	1.0000
14:77458271:T:G	donor_loss	1.0000
14:77459611:TGCAG:T	acceptor_loss	1.0000
14:77459612:GCA:G	acceptor_loss	1.0000
14:77459614:A:AC	acceptor_loss	1.0000
14:77459614:A:AG	acceptor_gain	1.0000
14:77459614:AG:A	acceptor_gain	1.0000
14:77459614:AGGAC:A	acceptor_gain	1.0000
14:77459615:G:GT	acceptor_gain	1.0000
14:77459615:GG:G	acceptor_gain	1.0000
14:77459615:GGAC:G	acceptor_gain	1.0000
14:77459615:GGACG:G	acceptor_gain	1.0000
14:77459802:GACAG:G	donor_gain	1.0000
14:77459804:CAGGT:C	donor_loss	1.0000
14:77459805:AGGTA:A	donor_loss	1.0000
14:77459807:G:GG	donor_gain	1.0000
14:77459807:GT:G	donor_loss	1.0000
14:77459808:T:A	donor_loss	1.0000
14:77462636:A:AG	acceptor_gain	1.0000
14:77462641:GATTA:G	acceptor_gain	1.0000
14:77462757:CAGGT:C	donor_loss	1.0000
14:77462758:AGG:A	donor_loss	1.0000
14:77462759:GGTA:G	donor_loss	1.0000
14:77462760:G:GC	donor_loss	1.0000
14:77462761:T:G	donor_loss	1.0000

AlphaMissense

2216 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:77458220:T:A	W11R	1.000
14:77458220:T:C	W11R	1.000
14:77458222:G:C	W11C	1.000
14:77458222:G:T	W11C	1.000
14:77458252:C:A	N21K	1.000
14:77458252:C:G	N21K	1.000
14:77458262:T:A	W25R	1.000
14:77458262:T:C	W25R	1.000
14:77458264:G:C	W25C	1.000
14:77458264:G:T	W25C	1.000
14:77458265:C:A	H26N	1.000
14:77458265:C:G	H26D	1.000
14:77459616:G:C	W27C	1.000
14:77459616:G:T	W27C	1.000
14:77459752:C:A	R73S	1.000
14:77459752:C:G	R73G	1.000
14:77459753:G:C	R73P	1.000
14:77459755:A:G	K74E	1.000
14:77459756:A:T	K74I	1.000
14:77459757:A:C	K74N	1.000
14:77459757:A:T	K74N	1.000
14:77458217:C:A	R10S	0.999
14:77458221:G:C	W11S	0.999
14:77458241:G:C	D18H	0.999
14:77458250:A:G	N21D	0.999
14:77458254:T:A	V22D	0.999
14:77458257:A:T	N23I	0.999
14:77458263:G:C	W25S	0.999
14:77458266:A:G	H26R	0.999
14:77458267:C:A	H26Q	0.999

dbSNP variants (sampled 300 via entrez): RS1000084027 (14:77461006 A>C,G), RS1000438011 (14:77467066 G>A), RS1000486366 (14:77469461 A>G,T), RS1000715392 (14:77458137 G>C), RS1001529122 (14:77460545 T>C), RS1002563391 (14:77468924 T>G), RS1002616016 (14:77462314 A>G,T), RS1002663980 (14:77464694 G>A), RS1003204456 (14:77459173 C>G,T), RS1003903692 (14:77458954 T>C), RS1004012445 (14:77461531 CG>C,CGG), RS1004182366 (14:77467140 T>G), RS1004669579 (14:77468962 C>T), RS1004683929 (14:77462946 T>A,C,G), RS1004906979 (14:77457700 C>A)

Disease associations

OMIM: gene MIM:608466 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3309113 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 3 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.52	IC50	300	nM	CHEMBL4536929

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[[1-(4-fluorophenyl)pyrrole-2-carbonyl]amino]-3-[3-(trifluoromethyl)phenyl]thiourea	2100615: Inhibition of human recombinant Aha1 expressed in Escherichia coli BL21 (DE3)	ic50	0.3000	uM

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases reaction, affects cotreatment, increases abundance, increases expression, affects binding	4
Tobacco Smoke Pollution	increases expression	3
Cyclosporine	increases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
bisphenol A	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
cupric oxide	increases phosphorylation	1
celastrol	increases expression	1
microcystin RR	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-phenylbutyric acid	increases expression	1
azoxystrobin	increases expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	increases expression	1
gedunin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
picoxystrobin	increases expression	1
PCI 5002	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Temozolomide	increases expression	1
Acetaminophen	affects response to substance	1
Air Pollutants	increases abundance, increases expression	1
Antimycin A	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3379288	Binding	Binding affinity to Aha1 (unknown origin) using FITC-labeled compound up to 5 uM by fluorescence polarization assay	Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix. — Bioorg Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1PV	HAP1 AHSA1 (-) 2	Cancer cell line	Male
CVCL_E1PW	HAP1 AHSA1 (-) 3	Cancer cell line	Male
CVCL_E1PX	HAP1 AHSA1 (-) 4	Cancer cell line	Male
CVCL_XL14	HAP1 AHSA1 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.